Targeting CD19 with genetically modified EBV-specific human T lymphocytes

Ann Hematol. 2002;81 Suppl 2:S42-3.


Human Epstein-Barr virus-specific T cells were genetically modified to express chimeric receptors specific for human CD19, which is expressed on the cell surface of most B cell malignancies. The receptor-modified EBV-specific T cells can be expanded and maintained long term in the presence of EBV-infected B cells. They recognize autologous EBV-infected targets through their conventional T cell receptor, and allogeneic EBV-infected targets and tumor targets through their chimeric receptor. They efficiently lyse both EBV and CD19-positive tumor targets in the absence of background cytotoxicity against CD19-negative targets. Donor-derived EBV-specific T cells expressing chimeric anti-tumor receptors may represent a source of effector cells that could be safely administered to leukemia patients to eradicate minimal residual disease after allogeneic bone marrow transplantation.

MeSH terms

  • Antigens, CD19 / genetics*
  • Gene Expression
  • Herpesvirus 4, Human / immunology*
  • Humans
  • Immunoglobulin Fragments / genetics
  • Immunoglobulin G / genetics
  • Immunotherapy, Adoptive
  • Leukemia / therapy
  • Neoplasm, Residual / therapy
  • Receptors, Fc / genetics
  • Recombinant Fusion Proteins
  • Stem Cell Transplantation
  • T-Lymphocytes / metabolism*
  • Transfection*


  • Antigens, CD19
  • Immunoglobulin Fragments
  • Immunoglobulin G
  • Receptors, Fc
  • Recombinant Fusion Proteins
  • immunoglobulin Fv